Wu Haopeng, Guan Zhihui, Zhang Kai, Zhou Lingmin, Cao Lanxin, Mou Xiongneng, Cui Wei, Tian Baoping, Zhang Gensheng
Department of Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Department of Emergency Medicine, the First People's Hospital of Taizhou, Taizhou, China.
PeerJ. 2025 Feb 17;13:e18874. doi: 10.7717/peerj.18874. eCollection 2025.
To evaluate the effect of perioperative probiotics or synbiotics on the incidence of postoperative infections following major liver surgery.
Meta-analysis.
PubMed, Embase, Scopus, and the Cochrane Library for relevant English-language studies published up to February 21st, 2024.
Randomized controlled trials evaluating perioperative probiotics or synbiotics for preventing postoperative infections in patients undergoing major liver surgery.
Outcomes included postoperative infection incidence, antibiotic therapy duration, length of stay in intensive care unit (ICU) and hospital. A random-effect model was adopted for the meta-analysis. The quality of included studies was evaluated using the Cochrane risk of bias tool.
Ten studies involving 588 patients were included. Pooled analyses revealed that perioperative probiotics or synbiotics significantly reduced postoperative infection incidence (RR 0.36, 95% CI [0.24-0.54], < 0.0001, I = 6%) and antibiotic therapy duration (MD -2.82, 95% CI [-3.13 to -2.51], < 0.001, I = 0%). No significant differences were observed in length of stay in ICU (MD -0.25, 95% CI [-0.84-0.34], = 0.41, I = 64%) or length of stay in hospital (MD -1.25, 95% CI [-2.74-0.25], = 0.10, I = 56%).
This meta-analysis suggests that perioperative administration of probiotics or synbiotics may reduce the incidence of postoperative infections and duration of antibiotic therapy. Their use as adjunctive therapy during the perioperative period could be considered for patients undergoing major liver surgery.
评估围手术期使用益生菌或合生元对大肝脏手术后感染发生率的影响。
荟萃分析。
截至2024年2月21日在PubMed、Embase、Scopus和Cochrane图书馆发表的相关英文研究。
评估围手术期使用益生菌或合生元预防大肝脏手术患者术后感染的随机对照试验。
结局指标包括术后感染发生率、抗生素治疗时长、重症监护病房(ICU)住院时长和住院时长。荟萃分析采用随机效应模型。使用Cochrane偏倚风险工具评估纳入研究的质量。
纳入10项研究,共588例患者。汇总分析显示,围手术期使用益生菌或合生元可显著降低术后感染发生率(风险比0.36,95%置信区间[0.24 - 0.54],P < 0.0001,I² = 6%)和抗生素治疗时长(平均差 -2.82,95%置信区间[-3.13至-2.51],P < 0.001,I² = 0%)。在ICU住院时长(平均差 -0.25,95%置信区间[-0.84 - 0.34],P = 0.41,I² = 64%)或住院时长(平均差 -1.25,95%置信区间[-2.74 - 0.25],P = 0.10,I² = 56%)方面未观察到显著差异。
这项荟萃分析表明,围手术期使用益生菌或合生元可能降低术后感染发生率和抗生素治疗时长。对于接受大肝脏手术的患者,可考虑将其作为围手术期辅助治疗手段。